Remote Ischaemic Conditioning in Septic Shock Septic shock is one of the most severe complications of any infection. It affects millions of people each year. Studies show that in the U.S. and Europe, nearly 10% of patients admitted to the ICU have septic shock. Significant efforts have been made to recognise and treat septic shock early. Still, over 50% of patients die of septic shock within days or weeks after diagnosis. Thus, there is a need for new therapeutic a...

Surge Mechanical Ventilation During COVID-19 During the COVID-19 pandemic, many hospitals in the U.S. exceeded their mechanical ventilation capability. As COVID-19 spread to communities with limited immunity, challenges associated with providing surge mechanical ventilation were reported. Hospitals, healthcare systems, and jurisdictional authorities purchased more ventilators. But the fear that the supply would not be able to fulfill the demand conti...

ARTICLES|ONLINE FIRST Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial Toby M Maher, Veronica A Tudor, Peter Saunders, et al. Lancet Respir Med Published:November 11, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00359-9 Summary Background Rituximab is often used as rescue therapy in in...

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial  Marisa Holubar,  Aruna Subramanian,  Natasha Purington,  et al Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1883–1892, https://doi.org/10.1093/cid/ciac312 Abstract Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitroactivity...

Clinical Nutrition Issues in 2022 Critically ill patients are fed with amounts below the recommendations of international guidelines. To overcome large energy deficits, supplemental parenteral nutrition (SPN) to top up enteral nutrition (EN) has been proposed. This strategy is included in both the American (ASPEN) and European (ESPEN) clinical nutrition guidelines.  SPN has demonstrated clinical benefits and is included in the American and European guidelin...

Research Changing patterns in reporting and sharing of review data in systematic reviews with meta-analysis of the effects of interventions: cross sectional meta-research study Phi-Yen Nguyen, Raju Kanukula, Joanne E McKenzie, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-072428 (Published 22 November 2022)Cite this as: BMJ 2022;379:e072428 Abstract Objectives To examine changes in completeness of reporting and frequency of sharing data, an...

ORIGINAL ARTICLE Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network N Engl J Med January 21, 2023DOI: 10.1056/NEJMoa2212663 Abstract BACKGROUND Intravenous fluids and vasopressor agents are commonly used in early resuscitation of patients with sepsis, but comparative data for prioritizing their delivery are l...

Research Impact of community asymptomatic rapid antigen testing on covid-19 related hospital admissions: synthetic control study Xingna Zhang, Ben Barr, Mark Green, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-071374 (Published 23 November 2022)Cite this as: BMJ 2022;379:e071374 Abstract Objective To analyse the impact of voluntary rapid testing for SARS-CoV-2 antigen in Liverpool city on covid-19 related hospital admissions. Design&nbs...

Vitamin D Supplements and Risk of COVID-19 Findings from two large clinical trials show that increasing vitamin D levels in adults during the COVID-19 pandemic was not associated with protection against coronavirus or other respiratory tract infections.  Vitamin D has long been recognised to support innate immune responses to respiratory viruses and bacteria. Some studies show that vitamin D may protect against respiratory tract infections, particularly amo...

ARTICLES| VOLUME 10, ISSUE 12, P1137-1146, DECEMBER 01, 2022 Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Alexander P J Vlaar, Martin Witzenrath, Pieter van Paassen, et al. Lancet Respir Med 2022; 10: 1137-1146 Published:September 07, 2022 DOI: https://doi.org/10.1016/S2213-2600(22)00297-1 ...